	US 12,357,566 B2
	Use of encapsulated cell therapy for treatment of ophthalmic disorders
Jeffrey Louis Goldberg, San Diego, CA (US); Cahil McGovern, North Kingstown, RI (US); Weng Tao, Lincoln, RI (US); and Konrad A Kauper, Sutton, MA (US)
Assigned to Neurotech USA, Inc., Cumberland, RI (US)
Filed by Neurotech USA, Inc., Cumberland, RI (US)
Filed on Dec. 4, 2023, as Appl. No. 18/527,884.
Application 18/527,884 is a continuation of application No. 17/529,402, filed on Nov. 18, 2021, abandoned.
Application 17/529,402 is a continuation of application No. 16/563,048, filed on Sep. 6, 2019, granted, now 11,207,266, issued on Dec. 28, 2021.
Application 16/563,048 is a continuation of application No. 15/166,790, filed on May 27, 2016, granted, now 10,456,356, issued on Oct. 29, 2019.
Claims priority of provisional application 62/167,213, filed on May 27, 2015.
Prior Publication US 2024/0285521 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61F 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/30 (2015.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01)

CPC A61K 9/0051 (2013.01) [A61F 9/0017 (2013.01); A61K 9/4816 (2013.01); A61K 35/30 (2013.01); A61K 38/185 (2013.01); A61K 38/19 (2013.01); A61K 38/2066 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01)]

15 Claims

1. A method of treating age-related macular degeneration (AMD) in a patient suffering therefrom comprising: implanting into an eye of the patient a biocompatible device comprising

a) a core comprising between 5×10²and 6×10⁵ARPE-19 cells that are genetically engineered to secrete a therapeutically effective amount of ciliary neurotrophic factor (CNTF), wherein the therapeutically effective amount of CNTF is between 0.1 ng/eye/day and 50 ng/eye/day;

b) a semi-permeable membrane surrounding the core, wherein the membrane has a molecular weight cut off of 1-150 kD and permits the diffusion of the CNTF therethrough and wherein the semi-permeable membrane is between 90 and 120 μm thick; and

c) a matrix disposed within the semi-permeable membrane, wherein the matrix comprises monofilaments twisted into a yarn that is in non-woven strands, wherein the cells are distributed on the monofilaments, and wherein the monofilaments comprise polyethylene terephthalate;

wherein said biocompatible device produces therapeutically effective amounts of the CNTF for at least 12 months post implantation.